Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.

[1]  T. Ishida,et al.  N4-Behenoyl-1-β-d-arabinofuranosylcytosine as a Potential New Antitumor Agent , 1977 .

[2]  P. Schein.  Preclinical toxicology of anticancer agents. , 1977, Cancer research.

[3]  T. Ishida,et al.  Antitumor activities of newly synthesized N4-acyl-1-beta-D-arabinofuranosylcytosine. , 1976, Cancer research.

[4]  Hutchison Dj,et al.  Microbiologic assay for cytosine arabinoside (NSC-63878): the use of a mutant of streptococcus faecium var. durans resistant to methotrexate (NSC-740) and 6-mercaptopurine (NSC-755). , 1975 .

[5]  E. Freireich,et al.  Clinical pharmacology of O2,2'‐cyclocytidine , 1975, Clinical pharmacology and therapeutics.

[6]  J. Burchenal,et al.  Oral and parenteral activity of 2,2'-anhydro-1- -D-arabinofuranosyl-5-fluorocytosine against both intraperitoneally and intracerebrally inoculated mouse leukemia. , 1972, Cancer research.

[7]  A. Hoshi,et al.  Antitumor activity of cyclocytidine in a variety of tumors. , 1972, Gan.

[8]  D. Ho,et al.  Clinical pharmacology of l‐β‐D‐arabinofuranosyl cytosine , 1971 .

[9]  C. Spurr,et al.  Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. , 1968, Blood.

[10]  A. R. Hanze.  Nucleic acids. IV. The catalytic reduction of pyrimidine nucleosides (human liver deaminase inhibitors). , 1967, Journal of the American Chemical Society.

[11]  J. Evans,et al.  The Effect of 1-β-d-Arabinofuranosylcytosine Hydrochloride on Murine Neoplasms , 1964 .

[12]  H. Skipper,et al.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. , 1964, Cancer chemotherapy reports.

[13]  H. Skipper,et al.  Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. , 1963, Cancer research.